SciVision Biotech Inc.'s product,?CREATEFILL? which can stimulate autologous collagen production, has obtained the Medical Device License of class III medical devices. Cause of occurrence: The dermal filler product, CREATEFILL, stimulates autologous collagen production, developed and manufactured by the company,has
obtained the Medical Device License of class III medical devices issued by the Ministry of Health and Welfare of the Republic of China (TFDA). (MOHW-MD-No.008137). Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The product contains poly-L-lactic acid, which stimulates the production of autologous collagen and elastic fibers after injection. It is suitable for addressing volume loss and signs of facial fat depletion (lipoatrophy) in concave areas of the face. This product will provide doctors and consumers with more choices and expand the applications of dermal filler products, which can increase domestic market sales performance and contribute to the company's revenue. Date of occurrence of the event: April 09, 2024.